MicroRNA-485-5p inhibits glioblastoma progression by suppressing E2F transcription factor 1 under cisplatin treatment

Bioengineered. 2021 Dec;12(1):8020-8030. doi: 10.1080/21655979.2021.1982269.

Abstract

Cisplatin (CDDP) has been widely used for glioblastoma treatment. miR-485-5p and E2F transcription factor 1 (E2F1) dysfunction has been reported in glioblastoma. Nonetheless, whether CDDP affects glioblastoma progression via the miR-485-5p-E2F1 axis requires investigation. The expression of miR-485-5p and E2F1 was investigated by quantitative real-time polymerase chain reaction or western blotting in glioblastoma tissues and cell lines. The interaction between miR-485-5p and E2F1 was confirmed using a luciferase assay. The malignancy of glioblastoma was detected using Cell Counting Kit-8, bromodeoxyuridine (BrdU), cell adhesion, flow cytometry, and transwell assays. We identified miR-485-5p downregulation and E2F1 upregulation in glioblastoma, and miR-485-5p inhibited cell growth and elevated cell apoptosis in glioblastoma cells after CDDP treatment. Moreover, miR-485-5p targeting E2F1 repressed cell growth and improved cell apoptosis in glioblastoma cells after CDDP treatment. Our study revealed that CDDP retarded glioblastoma cell development via the miR-485-5p-E2F1 axis, which may be a new direction for glioblastoma therapy.

Keywords: Cisplatin; cell growth; e2f1; glioblastoma; miR-485-5p.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Brain Neoplasms / drug therapy
  • Brain Neoplasms / genetics*
  • Cell Line, Tumor
  • Cell Movement
  • Cell Proliferation / drug effects
  • Cell Survival / drug effects
  • Cisplatin / pharmacology*
  • E2F1 Transcription Factor / genetics*
  • Female
  • Gene Expression Regulation, Neoplastic / drug effects
  • Glioblastoma / drug therapy
  • Glioblastoma / genetics*
  • Humans
  • Male
  • MicroRNAs / genetics*

Substances

  • E2F1 Transcription Factor
  • E2F1 protein, human
  • MIRN485 microRNA, human
  • MicroRNAs
  • Cisplatin

Grants and funding

This work was supported by Hubei Provincial Health Research Project (Grant number: WJ2019H331) and Wuhan Municipal Health Research Project (Grant number: WX19A16).